These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34129365)

  • 1. Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial.
    Ferreira JP; Lamiral Z; McMurray JJV; Swedberg K; van Veldhuisen DJ; Vincent J; Rossignol P; Pocock SJ; Pitt B; Zannad F
    Circ Heart Fail; 2021 Jun; 14(6):e008075. PubMed ID: 34129365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns.
    Ferreira JP; Duarte K; McMurray JJV; Pitt B; van Veldhuisen DJ; Vincent J; Ahmad T; Tromp J; Rossignol P; Zannad F
    Circ Heart Fail; 2018 Jul; 11(7):e004926. PubMed ID: 29997240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effectiveness of Eplerenone vs Spironolactone on Left Ventricular Systolic Function, Hospitalization and Cardiovascular Death in Patients With Chronic Heart Failure-HFrEF.
    Naser N; Durak-Nalbantic A; Sabanovic-Bajramovic N; Karic A
    Med Arch; 2023 Apr; 77(2):105-111. PubMed ID: 37260796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
    Chin KL; Collier TJ; Pitt B; McMurray JJ; Swedberg K; van Veldhuisen DJ; Pocock SJ; Vincent J; Turgonyi E; Zannad F; Krum H;
    Eur J Heart Fail; 2016 Sep; 18(9):1175-81. PubMed ID: 26833642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations.
    Rogers JK; McMurray JJ; Pocock SJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
    Circulation; 2012 Nov; 126(19):2317-23. PubMed ID: 23042980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Preiss D; van Veldhuisen DJ; Sattar N; Krum H; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
    Eur J Heart Fail; 2012 Aug; 14(8):909-15. PubMed ID: 22611047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
    Collier TJ; Pocock SJ; McMurray JJ; Zannad F; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pitt B
    Eur Heart J; 2013 Sep; 34(36):2823-9. PubMed ID: 23864130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eplerenone in patients with systolic heart failure and mild symptoms.
    Zannad F; McMurray JJ; Krum H; van Veldhuisen DJ; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B;
    N Engl J Med; 2011 Jan; 364(1):11-21. PubMed ID: 21073363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visit-to-visit blood pressure variation and outcomes in heart failure with reduced ejection fraction: findings from the Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms trial.
    Monzo L; Ferreira JP; Abreu P; Szumski A; Böhm M; McMurray JJV; Pitt B; Swedberg K; van Veldhuisen DJ; Girerd N; Vincent J; Zannad F; Rossignol P
    J Hypertens; 2020 Mar; 38(3):420-425. PubMed ID: 31584516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
    Olivier A; Pitt B; Girerd N; Lamiral Z; Machu JL; McMurray JJV; Swedberg K; van Veldhuisen DJ; Collier TJ; Pocock SJ; Rossignol P; Zannad F; Pizard A
    Eur J Heart Fail; 2017 Sep; 19(9):1186-1197. PubMed ID: 28303624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction.
    Matsumoto S; Kondo T; Jhund PS; Campbell RT; Swedberg K; van Veldhuisen DJ; Pocock SJ; Pitt B; Zannad F; McMurray JJV
    J Am Coll Cardiol; 2023 Sep; 82(11):1080-1091. PubMed ID: 37642608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
    Girerd N; Collier T; Pocock S; Krum H; McMurray JJ; Swedberg K; Van Veldhuisen DJ; Vincent J; Pitt B; Zannad F
    Eur Heart J; 2015 Sep; 36(34):2310-7. PubMed ID: 26093641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trial.
    Monzo L; Girerd N; Duarte K; Ferreira JP; McMurray JJV; van Veldhuisen DJ; Swedberg K; Pocock SJ; Pitt B; Zannad F
    Eur J Heart Fail; 2023 Aug; 25(8):1444-1449. PubMed ID: 37370197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study.
    Krum H; Shi H; Pitt B; McMurray J; Swedberg K; van Veldhuisen DJ; Vincent J; Pocock S; Zannad F;
    Circ Heart Fail; 2013 Jul; 6(4):711-8. PubMed ID: 23625945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.
    Dhillon S
    Drugs; 2013 Sep; 73(13):1451-62. PubMed ID: 23881669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Anand IS; Liu L; Pitt B; Pfeffer MA; Solomon SD
    Circulation; 2015 Aug; 132(5):402-14. PubMed ID: 26130119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
    Cannon JA; Collier TJ; Shen L; Swedberg K; Krum H; Van Veldhuisen DJ; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
    Eur J Heart Fail; 2015 Jul; 17(7):707-16. PubMed ID: 26139584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate.
    Chin KL; Collier T; Pocock S; Pitt B; McMurray JJV; van Veldhuisen DJ; Swedberg K; Vincent J; Zannad F; Liew D
    Clin Res Cardiol; 2019 Jul; 108(7):806-814. PubMed ID: 30604047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.